Compare Biogen Inc (BIIB) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Trade Desk Inc — how do they compare? Biogen Inc trades at $206.6 (market cap $30.13B), while Trade Desk Inc trades at $13.41 (market cap $6.37B). The key difference: Biogen Inc is far larger — about 4.7× Trade Desk Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | TTD | |
|---|---|---|
Market Cap | $30.13B | $6.37B |
Sector | Health | Technology |
52-Week High | $216.63 | $55.36 |
52-Week Low | $128.93 | $13.39 |
Enterprise Value | $37.20B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
The Trade Desk (TTD) stock trades at $13.33, near its 52-week low, reflecting a bearish technical trend with recent earnings misses and a 12% revenue decline guidance for Q3 2026. Despite strong profitability margins, the company faces execution gaps and competitive pressures in the ad-tech sector, leading to significant analyst downgrades and negative media sentiment.
Outlook remains cautious with high risk; potential exists if operational improvements reverse recent declines, but near-term headwinds from weak guidance and macroeconomic pressures suggest continued volatility. The stock's valuation appears reasonable, but investor confidence hinges on a demonstrated turnaround in revenue growth and execution stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
